| Published Application/Species/Sample/Dilution | Reference |
|---|
| Mahoney K, Shukla S, Patsoukis N, Chaudhri A, Browne E, Arazi A, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68:421-432 pubmed publisher |
| Desbois M, Giffon T, Yakkundi P, Denson C, Sekar K, Hart K, et al. IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells. Cancer Immunol Res. 2025;13:1172-1189 pubmed publisher |
| Tisci G, Rajsiglova L, Bibbo S, Ziccheddu G, Ricciardi E, Falvo E, et al. A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy. Int J Biol Macromol. 2025;309:142843 pubmed publisher |
| Ferrara Y, Latino D, Costagliola di Polidoro A, Oliver A, Sarnella A, Caprio M, et al. A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling. Cell Commun Signal. 2025;23:74 pubmed publisher |
| Mao C, Deng F, Zhu W, Xie L, Wang Y, Li G, et al. In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy. Nat Commun. 2024;15:9723 pubmed publisher |
| Sun M, Lv S, Pan Y, Song Q, Ma C, Yu M, et al. Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing. Bioorg Chem. 2024;153:107874 pubmed publisher |
| Xu X, Yan S, Yo Y, Chiang P, Tsai C, Lin L, et al. A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer. Cancers (Basel). 2024;16: pubmed publisher |
| Yao Y, Ren Y, Hou X, Wang P, Zhu J, Liu S, et al. Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2. Eur J Nucl Med Mol Imaging. 2024;52:36-47 pubmed publisher |
| Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer. 2024;12: pubmed publisher |
| Gu T, Tian X, Wang Y, Yang W, Li W, Song M, et al. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint. Front Immunol. 2023;14:1145028 pubmed publisher |
| Wang F, Ye W, He Y, Zhong H, Zhu Y, Han J, et al. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. Int J Mol Sci. 2023;24: pubmed publisher |
| Parkinson J, Hard R, Wang W. The RESP AI model accelerates the identification of tight-binding antibodies. Nat Commun. 2023;14:454 pubmed publisher |
| Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10: pubmed publisher |
| He B, Li B, Chen X, Zhang Q, Lu C, Yang S, et al. PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. Front Microbiol. 2022;13:928774 pubmed publisher |
| Jiao L, Dong Q, Zhai W, Zhao W, Shi P, Wu Y, et al. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy. Pharmacol Res. 2022;182:106343 pubmed publisher |
| Banta K, Xu X, Chitre A, Au Yeung A, Takahashi C, O Gorman W, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity. 2022;55:512-526.e9 pubmed publisher |
| Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, et al. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Front Immunol. 2021;12:778978 pubmed publisher |
| Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536 pubmed publisher |
| Jeong S, Park E, Kim H, Sung E, Kim H, Jeon J, et al. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. 2021;9: pubmed publisher |
| Sasikumar P, Sudarshan N, Adurthi S, Ramachandra R, Samiulla D, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4:699 pubmed publisher |
| Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, et al. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol. 2021;12:654463 pubmed publisher |
| Li M, Zhao R, Chen J, Tian W, Xia C, Liu X, et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Sci Rep. 2021;11:5774 pubmed publisher |
| Xing Y, Liu J, Sun S, Ming T, Wang Y, Luo J, et al. New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor. Bioelectrochemistry. 2021;140:107789 pubmed publisher |
| Gu T, Zhao S, Jin G, Song M, Zhi Y, Zhao R, et al. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Front Immunol. 2020;11:621441 pubmed publisher |
| Wang F, Ye W, Wang S, He Y, Zhong H, Wang Y, et al. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia. 2021;23:281-293 pubmed publisher |
| Schofield D, Percival Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs. 2021;13:1857100 pubmed publisher |
| Wu X, Li F, Li Y, Yu Y, Liang C, Zhang B, et al. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Med Sci Monit. 2020;26:e925583 pubmed publisher |
| Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219: pubmed publisher |
| Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019;51:1059-1073.e9 pubmed publisher |
| Hassounah N, Malladi V, Huang Y, Freeman S, Beauchamp E, Koyama S, et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother. 2019;68:407-420 pubmed publisher |
| Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, et al. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front Immunol. 2018;9:1614 pubmed publisher |
| Ansari N, Ghazvini K, Ramezani M, Shahdordizadeh M, Yazdian Robati R, Abnous K, et al. Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay. Mikrochim Acta. 2017;185:21 pubmed publisher |
| Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018;6:178-188 pubmed publisher |
| Haworth K, Arnold M, Pierson C, Choi K, Yeager N, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017;8:82037-82048 pubmed publisher |
| Shahdordizadeh M, Taghdisi S, Sankian M, Ramezani M, Abnous K. Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro. Int Immunopharmacol. 2017;53:96-104 pubmed publisher |
| Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget. 2017;8:41932-41946 pubmed publisher |
| Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7:64967-64976 pubmed publisher |
